精锋医疗港股IPO及境内未上市股份“全流通”获中国证监会备案

Group 1 - The core point of the news is that Shenzhen Precision Medical Technology Co., Ltd. plans to issue up to 31,880,500 overseas listed ordinary shares and list them on the Hong Kong Stock Exchange, while 49 shareholders intend to convert a total of 295,880,748 unlisted domestic shares into overseas listed shares for circulation [1][3] Group 2 - The company focuses on the design, development, and manufacturing of surgical robots, with its core product being the MP1000 multi-port laparoscopic surgical robot and the SP1000 single-port laparoscopic surgical robot as a key product under research [3] - According to Frost & Sullivan, the company is the first in China to complete critical clinical trials for both multi-port and single-port laparoscopic surgical robots [3] - Both MP1000 and SP1000 have qualified for expedited review by the National Medical Products Administration for innovative medical devices [3] - The company received registration approval from the National Medical Products Administration for MP1000 for use in urological surgeries in December 2022 [3] - The surgical robot market in China is highly competitive, with five companies having received approval for multi-port laparoscopic surgical robots, while no approvals have been granted for single-port laparoscopic surgical robots [3]